Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

155 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
"Real-world" data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group.
Katodritou E, Vadikolia C, Lalagianni C, Kotsopoulou M, Papageorgiou G, Kyrtsonis MC, Matsouka P, Giannakoulas N, Kyriakou D, Karras G, Anagnostopoulos N, Michali E, Briasoulis E, Hatzimichael E, Spanoudakis E, Zikos P, Tsakiridou A, Tsionos K, Anargyrou K, Symeonidis A, Maniatis A, Terpos E. Katodritou E, et al. Among authors: briasoulis e. Ann Hematol. 2014 Jan;93(1):129-39. doi: 10.1007/s00277-013-1841-y. Epub 2013 Jul 28. Ann Hematol. 2014. PMID: 23892921
Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival.
Katodritou E, Kyrtsonis MC, Delimpasi S, Kyriakou D, Symeonidis A, Spanoudakis E, Vasilopoulos G, Anagnostopoulos A, Kioumi A, Zikos P, Aktypi A, Briasoulis E, Megalakaki A, Repousis P, Adamopoulos I, Gogos D, Kotsopoulou M, Pappa V, Papadaki E, Fotiou D, Nikolaou E, Giannopoulou E, Hatzimichael E, Giannakoulas N, Douka V, Kokoviadou K, Timotheatou D, Terpos E. Katodritou E, et al. Among authors: briasoulis e. Ann Hematol. 2018 Sep;97(9):1671-1682. doi: 10.1007/s00277-018-3361-2. Epub 2018 May 13. Ann Hematol. 2018. PMID: 29756171 Free PMC article.
Correction to: Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival.
Katodritou E, Kyrtsonis MC, Delimpasi S, Kyriakou D, Symeonidis A, Spanoudakis E, Vasilopoulos G, Anagnostopoulos A, Kioumi A, Zikos P, Aktypi A, Briasoulis E, Megalakaki A, Repousis P, Adamopoulos I, Gogos D, Kotsopoulou M, Pappa V, Papadaki E, Fotiou D, Nikolaou E, Giannopoulou E, Hatzimichael E, Giannakoulas N, Douka V, Kokoviadou K, Timotheatou D, Terpos E. Katodritou E, et al. Among authors: briasoulis e. Ann Hematol. 2018 Sep;97(9):1747. doi: 10.1007/s00277-018-3404-8. Ann Hematol. 2018. PMID: 29943159 Free PMC article.
A retrospective study of azacitidine treatment in patients with intermediate-2 or high risk myelodysplastic syndromes in a real-world clinical setting in Greece.
Pappa V, Anagnostopoulos A, Bouronikou E, Briasoulis E, Kotsianidis I, Pagoni M, Zikos P, Tsionos K, Viniou N, Meletis J, Papadaki H, Kioumi A, Galanopoulos A, Vervessou EC, Poulakidas E, Karmas P, Karvounis K, Symeonidis A. Pappa V, et al. Among authors: briasoulis e. Int J Hematol. 2017 Feb;105(2):184-195. doi: 10.1007/s12185-016-2115-y. Epub 2016 Nov 4. Int J Hematol. 2017. PMID: 27815858
Megaloblastic anemia presenting with skin hyperpigmentation.
Hatzimichael E, Briasoulis E. Hatzimichael E, et al. Among authors: briasoulis e. Int J Hematol. 2016 May;103(5):479-80. doi: 10.1007/s12185-016-1977-3. Epub 2016 Mar 9. Int J Hematol. 2016. PMID: 26961325 No abstract available.
Metronomic chemotherapy beyond misconceptions.
Hatzimichael E, Briasoulis E. Hatzimichael E, et al. Among authors: briasoulis e. Haematologica. 2013 Nov;98(11):e145. doi: 10.3324/haematol.2013.096917. Haematologica. 2013. PMID: 24186318 Free PMC article. No abstract available.
Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial.
Dimopoulos MA, Richardson PG, Bahlis NJ, Grosicki S, Cavo M, Beksaç M, Legieć W, Liberati AM, Goldschmidt H, Belch A, Magen H, Larocca A, Laubach JP, Petrucci MT, Reece D, White D, Mateos MV, Špička I, Lazaroiu M, Berdeja J, Kaufman JL, Jou YM, Ganetsky A, Popa McKiver M, Lonial S, Weisel K; ELOQUENT-1 investigators. Dimopoulos MA, et al. Lancet Haematol. 2022 Jun;9(6):e403-e414. doi: 10.1016/S2352-3026(22)00103-X. Epub 2022 May 9. Lancet Haematol. 2022. PMID: 35550060 Free article. Clinical Trial.
Revisiting bleomycin from pathophysiology to safe clinical use.
Froudarakis M, Hatzimichael E, Kyriazopoulou L, Lagos K, Pappas P, Tzakos AG, Karavasilis V, Daliani D, Papandreou C, Briasoulis E. Froudarakis M, et al. Among authors: briasoulis e. Crit Rev Oncol Hematol. 2013 Jul;87(1):90-100. doi: 10.1016/j.critrevonc.2012.12.003. Epub 2013 Jan 9. Crit Rev Oncol Hematol. 2013. PMID: 23312772 Review.
155 results